Dr. Ryan Moy, M.D., PH.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 108
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 287759 -
Internal Medicine Physician
NY license 287759 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 108
- Services billed
- 471
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 99 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 88 | 30 |
| Established patient office or other outpatient visit, 40-54 minutes | 41 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in New York, NY | 14 |
| Prochlorperazine Maleate Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 19 payments worth $14,666 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $7,816 |
|---|---|
| Gilead Sciences, Inc. | $2,180 |
| Beone Medicines USA, Inc. | $2,055 |
| Novartis Pharmaceuticals Corporation | $1,564 |
| Amgen Inc. | $711 |
| AstraZeneca Pharmaceuticals LP | $226 |
| Exelixis Inc. | $114 |
| Consulting Fee | $12,581 |
|---|---|
| Travel and Lodging | $1,067 |
| Food and Beverage | $1,018 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jan 27, 2025 | Consulting Fee | $7,740 |
| Gilead Sciences, Inc. Oct 8, 2025 | Consulting FeeCompany’s description;4278099;VEM US;12675814 | $2,180 |
| Beone Medicines USA, Inc. Sep 24, 2025 | Consulting Fee TEVIMBRA · Oncology | $1,950 |
| Novartis Pharmaceuticals Corporation Mar 2, 2025 | Travel and Lodging travel to Miami, FL | $585 |
| Novartis Pharmaceuticals Corporation Jan 22, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $482 |
| Amgen Inc. May 6, 2025 | Consulting Fee | $368 |
| Amgen Inc. Aug 12, 2025 | Consulting Fee | $343 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $744,096 in research payments for these studies, mostly to the institutions running them.
- LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor
Novartis Pharmaceuticals Corporation - A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
AstraZeneca Pharmaceuticals LP - A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
E.r. Squibb & Sons, L.l.c. - A phase 1/2, first-in-human, open label, dose escalation study of MVC-101, an egfr x CD3 conditional bispecific redirected activation (cobratm) protein in patients with unresectable locally advanced or metastatic cancer
Takeda Pharmaceuticals U.S.A., Inc. - A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors
Novartis Pharmaceuticals Corporation - A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-…
Merck Sharp & Dohme LLC - A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarci…
Merck Sharp & Dohme LLC - A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Ad…
Merck Sharp & Dohme LLC - An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus (rNDV) Encoding Interleukin-12 (IL-12…
AstraZeneca Pharmaceuticals LP - Morpheus NeoAdj HCC
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.